Longboard Pharmaceuticals Announces FDA Granted Breakthrough Therapy Designation For Bexicaserin
- U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs)